Summit-logo-RGB.png
Summit Therapeutics Presents Ri-CoDIFy Trial Results for Microbiome-Sparing Ridinilazole at IDWeek 2022
20 oct. 2022 17h15 HE | Summit Therapeutics Inc.
Ridinilazole resulted in a 53% relative risk reduction in recurrence of C. difficile infection compared to treatment with vancomycin Ridinilazole preserved the gut microbiome compared to...
Summit-logo-RGB.png
Summit Therapeutics to Present Ri-CoDIFy Trial Results for Microbiome-Sparing Ridinilazole at IDWeek 2022
13 oct. 2022 08h00 HE | Summit Therapeutics Inc.
Menlo Park, California, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) and its product candidate, ridinilazole, will have an oral podium...
Summit-logo-RGB.png
Summit Therapeutics Appoints Dr. Maky Zanganeh as Co-CEO & President
26 juil. 2022 16h15 HE | Summit Therapeutics Inc.
Menlo Park, California, July 26, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) announces that Dr. Maky Zanganeh, DDS, MBA, has been appointed as Co-Chief Executive Officer &...
Summit-logo-RGB.png
Summit Therapeutics Announces Commencement of $100 Million Rights Offering
18 juil. 2022 16h05 HE | Summit Therapeutics Inc.
Menlo Park, CA, July 18, 2022 (GLOBE NEWSWIRE) --  Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that it has commenced its previously-announced rights offering of up to $100 million of the...
Summit-logo-RGB.png
Summit Therapeutics Provides Update on Ridinilazole
14 juil. 2022 08h30 HE | Summit Therapeutics Inc.
Menlo Park, CA, July 14, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” "we," or the “Company”) today provided an update with respect to the clinical development of...
Addison Group Expands Non-Clinical Healthcare Services With Acquisition of Harmony Healthcare
11 juil. 2022 06h00 HE | Addison Group
CHICAGO, July 11, 2022 (GLOBE NEWSWIRE) -- Addison Group ("Addison"), a national leader in professional services specializing in talent solutions and consulting services, announced today the...
IMC Logo.jpg
Immuron Receives European Patent Notification on Drug Composition to Treat Clostridioides difficile Associated Disease
07 juil. 2022 06h00 HE | Immuron Limited
MELBOURNE, Australia, July 07, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
Summit-logo-RGB.png
Summit Therapeutics Inc Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2022
11 mai 2022 16h30 HE | Summit Therapeutics Inc.
Cambridge, MA, May 11, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational...
Dolbey's Computer-Assisted Coding Ranks Best in KLAS for Six Years in a Row
15 févr. 2022 10h15 HE | Dolbey
CONCORD, Ohio, Feb. 15, 2022 (GLOBE NEWSWIRE) -- The Dolbey Fusion CAC computer-assisted coding solution has been ranked Best in KLAS for the sixth year in a row. Dolbey's Fusion CAC is utilized by...
Summit-logo-RGB.png
Summit Therapeutics Announces Topline Results for Phase III Ri-CoDIFy Study for C. Difficile Infection
20 déc. 2021 08h30 HE | Summit Therapeutics Inc.
Cambridge, MA, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) today announced topline results for the Phase III Ri-CoDIFy study evaluating its...